Amgen Inc. (AMGN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Amgen’s revenue went from $23.0B in fiscal 2016 to $36.8B in fiscal 2025, growth of about 5.4% a year.
Net income in fiscal 2025 was $7.7B, a net margin of 21.0%; the best year in this period was 2018 with $8.4B.
Over the twelve months to September 30, 2026, revenue was $38.9B and net income $9.4B.
Free cash flow was $8.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 28% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.9B | $36.8B | $33.4B | $28.2B | $26.3B | $26.0B | $25.4B | $23.4B | $23.7B | $22.8B | $23.0B |
| Gross profit | $27.6B | $24.7B | $20.6B | $19.7B | $19.9B | $19.5B | $19.3B | $19.0B | $19.6B | $18.8B | $18.8B |
| Operating income | $12.6B | $9.1B | $7.3B | $7.9B | $9.6B | $7.6B | $9.1B | $9.7B | $10.3B | $10.0B | $9.8B |
| Net income | $9.4B | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B | $7.3B | $7.8B | $8.4B | $2.0B | $7.7B |
| EPS (diluted) | $17.25 | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 |
| R&D | $7.8B | $7.3B | $6.0B | $4.8B | $4.4B | $4.8B | $4.2B | $4.1B | $3.7B | $3.6B | $3.8B |
| Revenue growth | — | +10.0% | +18.6% | +7.1% | +1.3% | +2.2% | +8.8% | −1.6% | +3.9% | −0.6% | +6.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.0B | $10.0B | $11.5B | $8.5B | $9.7B | $9.3B | $10.5B | $9.2B | $11.3B | $11.2B | $10.4B |
| Capital spending | -$2.5B | -$1.9B | -$1.1B | -$1.1B | -$936M | -$880M | -$608M | -$618M | -$738M | -$664M | -$738M |
| Free cash flow | $9.6B | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B | $9.9B | $8.5B | $10.6B | $10.5B | $9.6B |
| Dividends paid | $5.4B | $5.1B | $4.8B | $4.6B | $4.2B | $4.0B | $3.8B | $3.5B | $3.5B | $3.4B | $3.0B |
| Buybacks | — | $0 | $200M | $0 | $6.4B | $5.0B | $3.5B | $7.7B | $17.8B | $3.2B | $3.0B |
| Stock-based pay | $493M | $494M | $530M | $431M | $401M | $341M | $330M | $308M | $311M | $329M | $311M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $9.1B | $12.0B | $10.9B | $9.3B | $8.0B | $10.6B | $8.9B | $29.3B | $41.7B | $3.2B |
| Debt | — | $55.4B | $60.9B | $65.4B | $39.6B | $34.0B | $33.4B | $30.4B | $33.9B | $35.3B | $34.6B |
| Equity | — | $8.7B | $5.9B | $6.2B | $3.7B | $6.7B | $9.4B | $9.7B | $12.5B | $25.2B | $29.9B |
| Total assets | — | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B | $62.9B | $59.7B | $66.4B | $80.0B | $77.6B |
| Shares (diluted) | 546M | 542M | 541M | 538M | 541M | 573M | 590M | 609M | 665M | 735M | 754M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 70.9% | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% | 75.8% | 81.3% | 82.7% | 82.2% | 81.9% |
| Operating margin | 32.4% | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% | 43.6% | 42.6% |
| Net margin | 24.1% | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.4% | 8.7% | 33.6% |
| FCF margin | 24.6% | 22.0% | 31.1% | 26.1% | 33.4% | 32.3% | 38.9% | 36.5% | 44.5% | 46.0% | 41.8% |
| ROIC | — | 12.2% | 9.7% | 9.4% | 19.7% | 16.5% | 19.1% | 20.7% | 19.4% | 13.0% | 12.8% |
| ROE | — | 89.1% | 69.6% | 107.8% | 179.0% | 88.0% | 77.2% | 81.1% | 67.2% | 7.8% | 25.9% |
Frequently asked questions
What is Amgen’s annual revenue?
$36.8B in fiscal 2025 and $38.9B over the twelve months to September 30, 2026.
How much profit does Amgen make?
Net income was $7.7B in fiscal 2025 (net margin 21.0%).
Is Amgen’s revenue growing?
Yes: revenue rose 10.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.